Literature DB >> 35615490

Pharmacy Leadership Amid the Pandemic: Maintaining Patient Safety During Uncertain Times.

Irene Derrong Lin1, John B Hertig2.   

Abstract

The relentless surges of global severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections that caused the Covid-19 disease had pressured researchers and regulators to develop effective treatments quickly. While studying these therapies amid the pandemic, threats to patient care were reported, including (1) maintaining adequate safeguards as clinical effectiveness and safety data evolves, (2) risks from online counterfeit medications, and (3) disruption of the global pharmaceutical supply chain. This article discusses these patient safety threats and suggests strategies that promote patient safety, foster medication intelligence, and mitigate drug shortages. As the world continues to develop safe and effective treatments for Covid-19, patient safety is paramount. In response to the World Health Organization (WHO) Global Safety Challenge: Medication Without Harm, leaders must establish effective approaches to improve medication safety during the pandemic. Successfully integrating these leadership strategies with current practices allows pharmacy leaders to implement robust systems to reduce errors, prevent harm, and advocate for patient safety.
© The Author(s) 2021.

Entities:  

Keywords:  education; management; medication safety

Year:  2021        PMID: 35615490      PMCID: PMC9125128          DOI: 10.1177/00185787211037545

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN: 0018-5787


  21 in total

1.  ASHP guidelines on preventing medication errors in hospitals: Advancing medication safety to the next level.

Authors:  Michael R Cohen; Judy L Smetzer; Allen J Vaida
Journal:  Am J Health Syst Pharm       Date:  2018-10-01       Impact factor: 2.637

2.  ASHP guidelines on managing drug product shortages.

Authors:  Erin R Fox; Milena M McLaughlin
Journal:  Am J Health Syst Pharm       Date:  2018-07-30       Impact factor: 2.637

3.  India expands use of controversial drug for coronavirus despite safety concerns.

Authors:  Priyanka Pulla
Journal:  Nature       Date:  2020-06-03       Impact factor: 49.962

Review 4.  COVID-19 Supply Chain Considerations for Prescription Drugs in Dermatology.

Authors:  Andjela Egger; Michael Abrouk; Merrick Brodsky; Robert S Kirsner
Journal:  J Drugs Dermatol       Date:  2020-06-01       Impact factor: 2.114

5.  The third global patient safety challenge: tackling medication-related harm.

Authors:  Aziz Sheikh; Neelam Dhingra-Kumar; Edward Kelley; Marie Paule Kieny; Liam J Donaldson
Journal:  Bull World Health Organ       Date:  2017-08-01       Impact factor: 9.408

6.  The COVID-19 infodemic.

Authors: 
Journal:  Lancet Infect Dis       Date:  2020-07-17       Impact factor: 25.071

7.  Global drug shortages due to COVID-19: Impact on patient care and mitigation strategies.

Authors:  Hisham A Badreldin; Bassam Atallah
Journal:  Res Social Adm Pharm       Date:  2020-05-19

8.  The consequence of COVID-19 on the global supply of medical products: Why Indian generics matter for the world?

Authors:  Philippe J Guerin; Sauman Singh-Phulgenda; Nathalie Strub-Wourgaft
Journal:  F1000Res       Date:  2020-04-01

9.  A Pharmacovigilance Study of Hydroxychloroquine Cardiac Safety Profile: Potential Implication in COVID-19 Mitigation.

Authors:  Anand Prakash Singh; Sultan Tousif; Prachi Umbarkar; Hind Lal
Journal:  J Clin Med       Date:  2020-06-15       Impact factor: 4.241

10.  On Patient Safety: COVID-19 Exposes the Dangerous State of Drug and Device Supply Chains.

Authors:  James Rickert
Journal:  Clin Orthop Relat Res       Date:  2020-07       Impact factor: 4.755

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.